Lineage Cell Therapeutics (LCTX) Tops Q1 EPS by 1c
Tweet
Share
E-mailGet Alerts LCTX Hot Sheet
Join SI Premium – FREE
Lineage Cell Therapeutics (NYSE: LCTX) reported Q1 EPS of ($0.02), $0.01 better than the analyst estimate of ($0.03). Revenue for the quarter came in at $1.5 million versus the consensus estimate of $2.01 million.
For earnings history and earnings-related data on Lineage Cell Therapeutics (LCTX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Atkore Inc (ATKR) Tops Q3 EPS by 14c
- Barclays Downgrades First Interstate Bancsystems (FIBK) to Underweight
- RBC Capital Upgrades Legrand SA (LR:FP) (LGRDY) to Outperform
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
